Cannistra SA - Search Results

1

Advances in the management of epithelial ovarian cancer.

Berkenblit A, Cannistra SA. Berkenblit A, et al. Among authors: cannistra sa. J Reprod Med. 2005 Jun;50(6):426-38. J Reprod Med. 2005. PMID: 16050567 Review.

2

Cancer of the ovary.

Cannistra SA. Cannistra SA. N Engl J Med. 1993 Nov 18;329(21):1550-9. doi: 10.1056/NEJM199311183292108. N Engl J Med. 1993. PMID: 8155119 Review. No abstract available.

3

BAX protein expression and clinical outcome in epithelial ovarian cancer.

Tai YT, Lee S, Niloff E, Weisman C, Strobel T, Cannistra SA. Tai YT, et al. Among authors: cannistra sa. J Clin Oncol. 1998 Aug;16(8):2583-90. doi: 10.1200/JCO.1998.16.8.2583. J Clin Oncol. 1998. PMID: 9704707

4

Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.

Tung N, Berkowitz R, Matulonis U, Quartulli M, Seiden M, Kim Y, Niloff J, Cannistra SA. Tung N, et al. Among authors: cannistra sa. Gynecol Oncol. 2000 May;77(2):271-7. doi: 10.1006/gyno.2000.5778. Gynecol Oncol. 2000. PMID: 10785477 Clinical Trial.

5

Granulosa cell tumor of the ovary.

Schumer ST, Cannistra SA. Schumer ST, et al. Among authors: cannistra sa. J Clin Oncol. 2003 Mar 15;21(6):1180-9. doi: 10.1200/JCO.2003.10.019. J Clin Oncol. 2003. PMID: 12637488 Review.

6

Progress in the management of gynecologic cancer: consensus summary statement.

Cannistra SA, Bast RC Jr, Berek JS, Bookman MA, Crum CP, DePriest PD, Garber JE, Koh WJ, Markman M, McGuire WP 3rd, Rose PG, Rowinsky EK, Rustin GJ, Skates SJ, Vasey PA, King L. Cannistra SA, et al. J Clin Oncol. 2003 May 15;21(10 Suppl):129s-132s. doi: 10.1200/JCO.2003.04.003. J Clin Oncol. 2003. PMID: 12743127 No abstract available.

7

Phase I trial of docetaxel, carboplatin, and gemcitabine as first-line therapy for patients with high-risk epithelial tumors of müllerian origin.

Berkenblit A, Tung N, Kim Y, Feyler H, Niloff J, Berghe KV, Cannistra SA. Berkenblit A, et al. Among authors: cannistra sa. Gynecol Oncol. 2003 Jun;89(3):486-93. doi: 10.1016/s0090-8258(03)00138-0. Gynecol Oncol. 2003. PMID: 12798716 Clinical Trial.

8

Gene expression signature with independent prognostic significance in epithelial ovarian cancer.

Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann TA, Cannistra SA. Spentzos D, et al. Among authors: cannistra sa. J Clin Oncol. 2004 Dec 1;22(23):4700-10. doi: 10.1200/JCO.2004.04.070. Epub 2004 Oct 25. J Clin Oncol. 2004. PMID: 15505275

9

A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.

Berkenblit A, Seiden MV, Matulonis UA, Penson RT, Krasner CN, Roche M, Mezzetti L, Atkinson T, Cannistra SA. Berkenblit A, et al. Among authors: cannistra sa. Gynecol Oncol. 2004 Dec;95(3):624-31. doi: 10.1016/j.ygyno.2004.08.028. Gynecol Oncol. 2004. PMID: 15581974 Clinical Trial.

10

Cancer of the ovary.

Cannistra SA. Cannistra SA. N Engl J Med. 2004 Dec 9;351(24):2519-29. doi: 10.1056/NEJMra041842. N Engl J Med. 2004. PMID: 15590954 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

115 results

Search Page